| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 70377-0013-11 | 70377-0013 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2023 | In Use | |
| 00093-7768-24 | 00093-7768 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 10, 2020 | Sep 30, 2026 | In Use |
| 82249-0611-30 | 82249-0611 | Everolimus | Yulithira | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 11, 2026 | In Use | |
| 72603-0257-01 | 72603-0257 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2024 | In Use | |
| 63850-0059-01 | 63850-0059 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 5, 2021 | In Use | |
| 65219-0200-05 | 65219-0200 | Temsirolimus | Temsirolimus | Chemotherapy | Enzyme Inhibitor | mTOR | Intravenous | Nov 20, 2020 | In Use | ||
| 82249-0610-30 | 82249-0610 | Everolimus | Yulithira | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 11, 2026 | In Use | |
| 51991-0824-33 | 51991-0824 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 5, 2023 | In Use | |
| 63850-0058-01 | 63850-0058 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 5, 2021 | In Use | |
| 00078-0594-61 | 00078-0594 | Everolimus | Afinitor | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jul 9, 2010 | In Use | |
| 60219-2280-02 | 60219-2280 | Everolimus | EVEROLIMUS | 3.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jan 14, 2025 | In Use | |
| 70377-0011-23 | 70377-0011 | Everolimus | EVEROLIMUS | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | May 17, 2024 | In Use | |
| 82249-0612-30 | 82249-0612 | Everolimus | Yulithira | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 11, 2026 | In Use | |
| 63850-0059-04 | 63850-0059 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | May 26, 2023 | In Use | |
| 00245-0822-30 | 00245-0822 | Everolimus | TORPENZ | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 24, 2024 | In Use | |
| 00078-0594-51 | 00078-0594 | Everolimus | Afinitor | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jul 9, 2010 | In Use | |
| 00078-0567-51 | 00078-0567 | Everolimus | Afinitor | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 31, 2009 | In Use | |
| 70377-0010-22 | 70377-0010 | Everolimus | EVEROLIMUS | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2021 | In Use | |
| 70377-0013-23 | 70377-0013 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | May 17, 2024 | In Use | |
| 59676-0610-01 | 59676-0610 | Trabectedin | Yondelis | 0.05 mg/mL | Chemotherapy | Alkylating Agent | Natural Product | Intravenous | Oct 23, 2015 | In Use | |
| 60505-6423-00 | 60505-6423 | Trabectedin | EVDI | 0.05 mg/mL | Chemotherapy | Alkylating Agent | Natural Product | Intravenous | Jun 30, 2026 | In Use | |
| 51144-0020-01 | 51144-0020 | ENFORTUMAB VEDOTIN | PADCEV | 20.0 mg/2mL | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | Intravenous | Dec 18, 2019 | In Use | |
| 51144-0030-01 | 51144-0030 | ENFORTUMAB VEDOTIN | PADCEV | 30.0 mg/3mL | Immunotherapy | Drug Antibody Conjugate | Nectin-4 | Intravenous | Dec 18, 2019 | In Use | |
| 43598-0171-11 | 43598-0171 | Thiotepa | Thiotepa | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | Nov 1, 2022 | In Use | |
| 53964-0002-02 | 53964-0002 | Thiotepa | Tepadina | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | Jan 26, 2017 | Aug 1, 2018 | In Use |
Found 12611 results — Export these results
Home